Influenza
Conditions
Brief summary
This study will examine the feasibility of having parents and caregivers administer FluMist live intranasal vaccine to their children at home outside the traditional medical environment and without the involvement of medical personnel. The study will recruit patients and families that are already eligible to receive the FluMist vaccine. After consent is obtained and vaccine is given to the family, they will go home to administer vaccine to other members within 24 hours. Telephone follow up within 48 hours will confirm that vaccine was given successfully and within 9-12 days to assess patient preferences for giving vaccine at home and if there were any adverse events.
Interventions
BIOLOGICALFluMist
Subjects receiving Flumist vaccine
Sponsors
University of North Carolina
MedImmune LLC
University of North Carolina, Chapel Hill
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
1. The primary caregiver must be 18 years of age or older and willing to give written informed consent for study participation 2. The primary caregiver must be the parent or legal guardian of all the children in living in the household 3. All the children in the household who are 2 through 17 years of age must receive their primary care in the clinic 4. All the children in the household who are 2 through 17 years of age must have private insurance that will provide for the cost of influenza vaccination 5. There must be at least one member of the household who is 2 through 17 years of age, presenting for care in the clinic, eligible to receive Live Attenuated Influenza Vaccine (LAIV) and whose primary care giver is willing to administer LAIV to them in the clinic with supervision 6. There must be at least one family member of the household who is 2 through 17 years of age, not presenting for care in the clinic, eligible to receive LAIV and whose primary care giver is willing to administer LAIV to them in the in-home setting 7. There must be a working refrigerator in the household 8. The primary caregiver must have a working telephone number and be willing to be contacted for study follow-up by telephone or e-mail 9. The primary caregiver is available for the entire study period - 12 days following the last dose of LAIV to be administered to a child 10. The primary caregiver must agree to complete a 30 minute post vaccination assessment and an 8 day diary following vaccination for each child receiving LAIV.
Exclusion criteria
1\. Children in the family receive vaccine through Vaccines for Children program
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects That Reported Successful Home Vaccination With no Adverse Events | 0-12 days | We will assess the tolerability of giving the FluMist nasal vaccine at home by parents/caregivers to their children by performing telephone survey follow up. We will ask parents at both 24-48 hours and at 9-12 days after study visit and enrollment about any difficulties in giving FluMist at home and any adverse events encountered when giving FluMist at home. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects That Reported Ability to Successfully Administer FluMist Vaccine at Home | 0-12 days | This study will also assess the feasibility of having parents/caregivers administer Flumist vaccine outside a traditional medical environment and without the direct participation of medical personnel. We will ask parents by telephone survey at both 24-48 hours and at 9-12 days after study visit and enrollment about any difficulties in giving FluMist at home, about maintaining temperature and conditions proper for vaccine storage until administration. We will also ask about ease of vaccine disposal and about child preferences for receiving vaccine at home compared to at a dedicated medical visit. |
Countries
United States
Participant flow
Recruitment details
10/2014-1/2015
Participants by arm
| Arm | Count |
|---|---|
| FluMist Subjects receiving vaccine at home
FluMist: Subjects receiving Flumist vaccine | 41 |
| Total | 41 |
Baseline characteristics
| Characteristic | FluMist |
|---|---|
| Age, Categorical <=18 years | 41 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants |
| Sex: Female, Male Female | 18 Participants |
| Sex: Female, Male Male | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 10 / 41 |
| serious Total, serious adverse events | 0 / 41 |
Outcome results
Primary
Number of Subjects That Reported Successful Home Vaccination With no Adverse Events
We will assess the tolerability of giving the FluMist nasal vaccine at home by parents/caregivers to their children by performing telephone survey follow up. We will ask parents at both 24-48 hours and at 9-12 days after study visit and enrollment about any difficulties in giving FluMist at home and any adverse events encountered when giving FluMist at home.
Time frame: 0-12 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FluMist | Number of Subjects That Reported Successful Home Vaccination With no Adverse Events | 41 participants |
Secondary
Number of Subjects That Reported Ability to Successfully Administer FluMist Vaccine at Home
This study will also assess the feasibility of having parents/caregivers administer Flumist vaccine outside a traditional medical environment and without the direct participation of medical personnel. We will ask parents by telephone survey at both 24-48 hours and at 9-12 days after study visit and enrollment about any difficulties in giving FluMist at home, about maintaining temperature and conditions proper for vaccine storage until administration. We will also ask about ease of vaccine disposal and about child preferences for receiving vaccine at home compared to at a dedicated medical visit.
Time frame: 0-12 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FluMist | Number of Subjects That Reported Ability to Successfully Administer FluMist Vaccine at Home | 41 participants |